K

KeyMed Biosciences Inc
HKEX:2162

Watchlist Manager
KeyMed Biosciences Inc
HKEX:2162
Watchlist
Price: 38.2 HKD -3.29% Market Closed
Market Cap: 10.5B HKD
Have any thoughts about
KeyMed Biosciences Inc?
Write Note

KeyMed Biosciences Inc
Net Income (Common)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

KeyMed Biosciences Inc
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
K
KeyMed Biosciences Inc
HKEX:2162
Net Income (Common)
-ÂĄ359.4m
CAGR 3-Years
24%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Net Income (Common)
-ÂĄ6.7B
CAGR 3-Years
16%
CAGR 5-Years
-7%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Net Income (Common)
ÂĄ1.2B
CAGR 3-Years
23%
CAGR 5-Years
34%
CAGR 10-Years
N/A
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Net Income (Common)
ÂĄ1.8B
CAGR 3-Years
5%
CAGR 5-Years
N/A
CAGR 10-Years
23%
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Net Income (Common)
ÂĄ6B
CAGR 3-Years
-6%
CAGR 5-Years
26%
CAGR 10-Years
48%
Imeik Technology Development Co Ltd
SZSE:300896
Net Income (Common)
ÂĄ1.9B
CAGR 3-Years
62%
CAGR 5-Years
72%
CAGR 10-Years
N/A
No Stocks Found

KeyMed Biosciences Inc
Glance View

Market Cap
10.7B HKD
Industry
Biotechnology

Keymed Biosciences, Inc. is an investment holding company. The company is headquartered in Chengdu, Sichuan. The company went IPO on 2021-07-08. The firm focuses on the independent discovery and development of innovative biological therapies that address underserved medical needs in the autoimmune and oncology therapeutic areas. The firm has mastered in-house drug discovery and development technologies, including an innovative antibody discovery platform and a proprietary novel T cell engager (nTCE) bispecific antibody platform. The firm has also established a fully integrated platform covering the key functions of biopharmaceutical development. The firm's main products include CM310, CM326 and CMG901.

Intrinsic Value
37.36 HKD
Overvaluation 2%
Intrinsic Value
Price
K

See Also

What is KeyMed Biosciences Inc's Net Income (Common)?
Net Income (Common)
-359.4m CNY

Based on the financial report for Dec 31, 2023, KeyMed Biosciences Inc's Net Income (Common) amounts to -359.4m CNY.

What is KeyMed Biosciences Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 3Y
24%

Over the last year, the Net Income (Common) growth was -17%. The average annual Net Income (Common) growth rates for KeyMed Biosciences Inc have been 24% over the past three years .

Back to Top